Cancer drug cures orphan disease skin damage
An FDA-approved cancer drug stops light sensitivity of the skin in Cockayne syndrome (CS), an ultra-rare hereditary disease characterised by premature aging, German researchers report.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1185 entries already.
Entries by Thomas Gabrielczyk
Germany to pump 1bn into breakthrough innovation
/in News/by Thomas GabrielczykGermanys government announced that it will create an agency for breakthrough ("jump") innovation to foster technology transfer of risky research projects with high market potential into products.
Urovant Sciences licenses OAB gene therapy
/in News/by Thomas GabrielczykUrovant Sciences has licensed the global commercialisation rights for Ion Channel Innovations gene therapy hMaxi-K for patients with overactive bladder (OAB) symptoms who have failed oral pharmacologic therapy.
Roche and Affimed in US$5bn cancer deal
/in News/by Thomas GabrielczykRoches US arm Genentech has licenced Affimed NVs ROCK platform to add multivalent antibodies, which could activate the innate immune system, to its cancer pipeline.
Foundation launches £30m award
/in News/by Thomas GabrielczykThe British Heart Foundation (BHF) will tender £30m (33.2m) to tackle the suffering and devastation caused by heart and circulatory diseases.
FDA greenlights Shires HAE mAB Takhzyro
/in News/by Thomas GabrielczykOrphan drug leader Shire plc (Dublin), has received the FDAs approval for its antibody lanadelumab-flyo, which prevents hereditary angioedema (HAE) attacks.
Matrikines give hint to new asthma meds
/in News/by Thomas GabrielczykBlocking the extracellular matrix (ECM) enzyme leukotriene A4 hydrolase (LTA4H) dampens inflammation but promotes changes in the airways of mice with allergic asthma due to accumulation of the ECM degradation […]
Novo Nordisk joins Evotec as drug discovery partner
/in News/by Thomas GabrielczykNovo Nordisk and Evotec have joined forces to find new drugs in the lucrative diabetes and obesity markets.
Genkyotex cashes in 7.5m
/in News/by Thomas GabrielczykFrench Genkyotex SA has secured an 7.5m gross financing to expand the scope of its Phase II product GKT831 in Primary Biliary Cholangitis (PBC).
Roche’s Alecensa approved in China
/in News/by Thomas GabrielczykRoche AGs ALK blocker Alecensa (alectinib) has been granted market approval by China National Drug Administration as first line NSCLC monotherapy in patients with ALK-positive non small cell lung cancer (NSCLC)